Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma

BMC Gastroenterology

Yukio Osaki²  Akira Arimoto¹  Toru Kimura²  Ryuichi Kita²  Akihiro Nasu²  Sumio Saito²  Tetsuro Ishikawa²  Keiichi Hatamaru²  Shinichiro Henmi²  Azusa Sakamoto²  Fumihiro Matsuda²  Jun Nakajima²  Haruhiko Takeda²  Tadashi Inuzuka²  Hiroki Nishikawa² 

[1] Department of Surgery, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka, 543-0027, Japan;Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka, 543-0027, Japan

关键词: recurrence;    survival;    HCC;    surgical resection;    PRFA;   

Others  :  1113168
DOI  :  10.1186/1471-230X-11-143

 received in 2011-06-05, accepted in 2011-12-28,  发布年份 2011

【 摘 要 】

Background

The purpose of this investigation was to compare the outcome of percutaneous radiofrequency thermal ablation therapy (PRFA) with surgical resection (SR) in the treatment of single and small hepatocellular carcinoma (HCC).

Methods

We conducted a retrospective cohort study on 231 treatment naive patients with a single HCC ≤ 3 cm who had received either curative PRFA (162 patients) or curative SR (69 patients). All patients were regularly followed up after treatment at our department with blood and radiologic tests.

Results

The 1-, 3- and 5-year overall survival rates after PRFA and SR were 95.4%, 79.6% and 63.1%, respectively in the PRFA group and 100%, 81.4% and 74.6%, respectively in the SR group. The corresponding recurrence free survival rates at 1, 3 and 5 years after PRFA and SR were 82.0%, 38.3% and 18.0%, respectively in the PRFA group and 86.0%, 47.2% and 26.0%, respectively in the SR group. In terms of overall survival and recurrence free survival, there were no significant differences between these two groups. In comparison of PRFA group patients with liver cirrhosis (LC) (n = 127) and SR group patients with LC (n = 50) and in comparison of PRFA group patients without LC (n = 35) and SR group patients without LC (n = 19), there were also no significant differences between two groups in terms of overall survival and recurrence free survival. In the multivariate analysis of the risk factors contributing to overall survival, serum albumin level was the sole significant factor. In the multivariate analysis of the risk factors contributing to recurrence free survival, presence of LC was the sole significant factor. The rate of serious adverse events in the SR group was significantly higher than that in the PRFA group (P = 0.023). Hospitalization length in the SR group was significantly longer than in the PRFA group (P = 0.013).

Conclusions

PRFA is as effective as SR in the treatment of single and small HCC, and is less invasive than SR. Therefore, PRFA could be a first choice for the treatment of single and small HCC.

【 授权许可】

   
2011 Nishikawa et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Bosch X, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271-85.
• [2]Liver Cancer Study Group of Japan: Primary liver cancers in Japan. Cancer 1980, 45:2663-69.
• [3]Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J: Hepatic resection for hepatocellular carcinoma: an audit of 343 patients. Ann Surg 1995, 221:291-98.
• [4]Lau WY, Leung TW, Yu SC, Ho SK: Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 2003, 237:171-79.
• [5]Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A: Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long term results. Eur Radiol 2001, 11:914-21.
• [6]Nicoli N, Casari A, Marchiori L: Intraoperative and percutaneous radiofrequency thermal ablation in the treatment of hepatocellular carcinoma. Chir Ital 2000, 52:29-40.
• [7]Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ: Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations and complications. Ann Surg Oncol 2000, 7:593-600.
• [8]Rossi S, Buscarini E, Garbagnati F, Di Stasi M, Quaretti P, Rago M, Zangrandi A, Andreola S, Silverman D, Buscarini L: Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. Am J Roentgenol 1998, 170:1015-22.
• [9]Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M: A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005, 129:122-30.
• [10]Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005, (42):(5): 1208-1236.
• [11]Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K: Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer 2001, 91(7):1342-8.
• [12]Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY: A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006, 243:321-28.
• [13]Grazi GL, Ercolani G, Pierangeli F, Gaudio MD, Cescon M, Cavallari A, Mazziotti A: Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 2001, 234:71-8.
• [14]Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J: Hepatocellular carcinoma. Current management and perspectives for the future. Ann Surg 2011, 253:453-69.
• [15]Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings H, Laubenberger J, Zuber I, Blum HE, Bartolozzi C: Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 2003, 228:235-40.
• [16]Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC: Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004, 127:1714-23.
• [17]Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC: Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005, 54:1151-56.
• [18]Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, Bruix J, Barcelona Clínic Liver Cancer Group: Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004, 40:1352-60.
• [19]Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, Haji S: Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007, 72:98-103.
• [20]Guglielmi A, Ruzzenete A, Sandri M: Radiofrequency ablation for hepatocellular carcinoma in cirrhotic patients: prognostic factors for survival. J Gastrointest Surg 2007, 11:143-149.
• [21]Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ: Micrometastasis of solitary heaptocellular carcinoma and appropriate resection margin. World J Surg 2004, 28:376-81.
• [22]Regimbeu JM, Kianmanesh R, Farges O, Dondero F, Sauvanet A, Belghiti JSO: Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery 2002, 131:311-17.
• [23]Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, Sano K, Sugawara Y, Takayama T, Makuuchi M: Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005, 242:252-59.
• [24]Sasaki A, Kai S, Iwashita Y, Hirano S, Ohta M, Kitano S: Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer 2005, 103:299-306.
• [25]Morimoto M, Numata K, Sugimori K, Shirato K, Kokawa A, Oka H, Hirasawa K, Koh R, Nihommatsu H, Tanaka K: Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol 2007, 13:1003-09.
• [26]Lu MD, Kuang M, Liang LJ, Xie XY, Peng BG, Liu GJ, Li DM, Lai JM, Li SQ: Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial (in Chinese with English abstract). Zhonghua Yi Xue Za Zhi 2006, 86:801-05.
• [27]Montorsi M, Santambrogio R, Bianchi P, Donadon M, Moroni E, Spinelli A, Costa M: Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. J Gastrointest Surg 2005, 9:62-7.
• [28]Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Rhee JC, Choi D, Lim HK, Lee KW, Joh JW: Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005, 39:247-52.
• [29]Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A, Memeo V: Single hepatocelluar carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection? HPB (Oxford) 2007, 9:429-34.
• [30]Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y, Ikai I: Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatology 2008, 49:589-594.
• [31]Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y: A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010, 252:903-12.
• [32]Tateishi R, Shiina S, Teratani T Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M: Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005, 103:1201-09.